 |
Miconazole
new delivery system
|
|
|
| October 26, 2006
at 14:00 to 15:30 - Room Nizza |
| |
| 26/11SS - 14:00 |
Introduction
B. Dupont1, D. Costantini2
1Hôpital Necker 2Laboratoire Bioalliance
Pharma, Paris, France |
| |
| 27/11SS - 14:05 |
Miconazole
an antifungal reference
B. Dupont1, M. Ghannoum2
1Hôpital Necker, Paris, France 2Centre
for Medical Mycology, University Hospitals of Cleveland - Case Western
Reserve University, Cleveland, United States |
| |
| 28/11SS - 14:25 |
Loramyc
(Miconazole Lauriad)development rational
T. Croughs
Laboratoire Bioalliance Pharma, Paris, France |
| |
| 29/11SS - 14:30 |
HIV
patients Phase III results
B. Dupont
Hôpital Necker, Paris, France |
| |
| 30/11SS - 14:45 |
Head
and neck cancer patients Phase III results
R.J. Bensadoun
Centre Antoine Lacassagne, Nice, France |
| |
| 31/11SS - 15:00 |
Loramyc’s
place in oropharyngal candidiasis management
B. Dupont
Hôpital Necker, Paris, France |
| |
| 32/11SS - 15:20 |
Loramyc
and Bioalliance Pharma
D. Costantini
Laboratoire Bioalliance Pharma, Paris, France |
| |
|
Treatment
Options in Later Stages of HIV-Infection and Disease Complications
|
|
|
| October 26, 2006
at 14:00 to 15:30 - Room Strasbourg |
| |
| 33/12SS - 14:00 |
CCR-5
antagonism as new mechanism of action for anti-HIV therapeutic strategies
G. Fätkenheuer
Department 1 of Internal Medicine, University of Cologne, Köln,
Germany |
| |
| 34/12SS - 14:25 |
Maintenance
therapy with pegylated interferon-alfa2b in HCV-HIV coinfected patients
with cirrhosis
J. Rockstroh
Department of Medicine I, University of Bonn, Bonn, Germany |
| |
| 35/12SS - 14:50 |
New
treatment options for HIV-positive patients with invasive fungal
disease
O. Cornely
Medizinische Klinik der Universität, Köln, Germany |
| |